Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRC-2694-A + paclitaxel in recurrent/metastatic HNSCC post-ICI
NCT05283226Phase 2Recruiting
- Sponsor
- Natco Pharma Limited
- Start
- Sep 2022
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of NRC-2694-A in head and neck squamous cell carcinoma (HNSCC), sponsored by Natco Pharma Limited. Started Sep 2022; status: recruiting.
02
Drugs
NRC-2694-A
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05283226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05283226.